ContraFect Announces U.S. FDA Grants Breakthrough Therapy Designation to Exebacase for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia, Including Right-Sided Endocarditis GlobeNewswire
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study The Lancet
ContraFect Announces US FDA Grants Breakthrough Therapy Designation to Exebacase for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia, Including Right-Sided Endocarditis | Proteins and Peptides | News Channels PipelineReview.com
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study The Lancet
ContraFect Announces US FDA Grants Breakthrough Therapy Designation to Exebacase for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia, Including Right-Sided Endocarditis | Proteins and Peptides | News Channels PipelineReview.com
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study The Lancet
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study The Lancet
ContraFect Announces U.S. FDA Grants Breakthrough Therapy Designation to Exebacase for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia, Including Right-Sided Endocarditis GlobeNewswire
ContraFect Announces US FDA Grants Breakthrough Therapy Designation to Exebacase for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia, Including Right-Sided Endocarditis | Proteins and Peptides | News Channels PipelineReview.com
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study The Lancet
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study The Lancet
ContraFect Announces U.S. FDA Grants Breakthrough Therapy Designation to Exebacase for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia, Including Right-Sided Endocarditis GlobeNewswire
ContraFect Announces U.S. FDA Grants Breakthrough Therapy Designation to Exebacase for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia, Including Right-Sided Endocarditis GlobeNewswire
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study The Lancet
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study The Lancet
Dr. Thomas Cannell, President and CEO of Sesen Bio, to Host Conference Call to Provide Business Update Highlighting Regulatory Progress and Commercial Opportunity for Vicinium® Odessa American
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study The Lancet
ContraFect Announces US FDA Grants Breakthrough Therapy Designation to Exebacase for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia, Including Right-Sided Endocarditis | Proteins and Peptides | News Channels PipelineReview.com
Dr. Thomas Cannell, President and CEO of Sesen Bio, to Host Conference Call to Provide Business Update Highlighting Regulatory Progress and Commercial Opportunity for Vicinium® Yahoo Finance
ContraFect Announces US FDA Grants Breakthrough Therapy Designation to Exebacase for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia, Including Right-Sided Endocarditis | Proteins and Peptides | News Channels PipelineReview.com
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study The Lancet
Japan Exchange : Shionogi's FETROJA(R) (cefiderocol) Now Available for the Treatment of Complicated Urinary Tract Infections in the US marketscreener.com
Japan Exchange : Shionogi's FETROJA(R) (cefiderocol) Now Available for the Treatment of Complicated Urinary Tract Infections in the US marketscreener.com
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study The Lancet
Japan Exchange : Shionogi's FETROJA(R) (cefiderocol) Now Available for the Treatment of Complicated Urinary Tract Infections in the US marketscreener.com
Japan Exchange : Shionogi's FETROJA(R) (cefiderocol) Now Available for the Treatment of Complicated Urinary Tract Infections in the US marketscreener.com
Japan Exchange : Shionogi's FETROJA(R) (cefiderocol) Now Available for the Treatment of Complicated Urinary Tract Infections in the US marketscreener.com
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study The Lancet
Japan Exchange : Shionogi's FETROJA(R) (cefiderocol) Now Available for the Treatment of Complicated Urinary Tract Infections in the US marketscreener.com
Artificial intelligence yields new antibiotic: A deep-learning model identifies a powerful new drug that can kill many species of antibiotic-resistant bacteria Science Daily
Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections. Physician's Weekly
Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections. Physician's Weekly
Artificial intelligence yields new antibiotic: A deep-learning model identifies a powerful new drug that can kill many species of antibiotic-resistant bacteria Science Daily
Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections. Physician's Weekly
Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections. Physician's Weekly
First study of antimicrobial activity of ceftazidime-avibactam and ceftolozane-tazobactam against Pseudomonas aeruginosa isolated from patients with urinary tract infection in Tehran, Iran MD Linx
Bacterial flora of the nose and paranasal sinuses among patients over 65 years old with chronic rhinosinusitis who underwent endoscopic sinus surgery MD Linx
Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections. Physician's Weekly
Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections. Physician's Weekly
Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections. Physician's Weekly
Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections. Physician's Weekly
Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections. Physician's Weekly
Pseudomonas Aeruginosa Infection Treatment Market Analysis 2020-2026 with Industry Leaders Profiles, Growth Prospects, Size and Top Countries | Allergan, Teva Pharmaceutical Industries, Pfizer Weekly Wall